Autoantibodies can be present years to decades before the onset of disease manifestations in autoimmunity. This finding suggests that the initial autoimmune trigger involves a peripheral lymphoid component, which ultimately drives disease pathology in local tissues later in life. We show that Sjögren's syndrome manifestations that develop in aged NOD.H-2h4 mice were driven by and dependent on peripheral dysregulation that arose in early life. Specifically, elimination of spontaneous germinal centers in spleens of young NOD.H-2h4 mice by transient blockade of CD40 ligand (CD40L) or splenectomy abolished Sjögren's pathology of aged mice. Strikingly, a single injection of anti-CD40L at 4 weeks of age prevented tertiary follicle neogenesis and greatly blunted the formation of key autoantibodies implicated in glandular pathology, including anti-muscarinic receptor antibodies. Microarray profiling of the salivary gland characterized the expression pattern of genes that increased with disease progression and showed that early anti-CD40L greatly repressed B cell function while having a broader effect on multiple biological pathways, including interleukin-12 and interferon signaling. A single prophylactic treatment with anti-CD40L also inhibited the development of autoimmune thyroiditis and diabetes in NOD.H-2h4 and nonobese diabetic mice, respectively, supporting a key role for CD40L in the pathophysiology of several autoimmune models. These results strongly suggest that early peripheral immune dysregulation gives rise to autoimmune manifestations later in life, and for diseases predated by autoantibodies, early prophylactic intervention with biologics may prove efficacious.
INTRODUCTION
Primary Sjögren's syndrome (pSS) is a chronic autoimmune disorder affecting exocrine glands. The disease is characterized by periductal infiltration of salivary glands (sialadenitis) and lacrimal glands that destroy secretory function, leading to xerostomia/dry mouth and keratoconjunctivitis sicca/dry eyes (1) . The cells that inflame the salivary gland often organize into tertiary lymphoid structures (TLSs). TLSs act as inductive sites for autoreactive T cell-B cell interactions that drive plasma cell differentiation and production of autoantibodies, resulting in tissue damage. Early pioneering work showed that the salivary gland TLSs present in about one-quarter of pSS patients (28%) displayed germinal center-like areas with follicular dendritic cell (FDC) networks that are associated with increased inflammatory cell infiltration and elevated levels of autoantibodies (2) . Furthermore, these germinal center-like areas contained autoantibody-producing cells, suggesting that these plasmablasts differentiated locally in the TLSs of inflamed salivary gland (3) . Initiation and maintenance of germinal centers require the tumor necrosis factor (TNF) receptor superfamily member, CD40 (4-7), which is expressed by salivary gland TLSs in both human disease and animal models of pSS (8, 9) . CD40 is also expressed by salivary gland epithelial and endothelial cells (8, 10) . Elucidation of the cellular and molecular events leading to TLS neogenesis and the role of CD40 is critical for understanding autoimmune pathophysiology.
Autoantibodies that arise in autoimmunity, such as type 1 diabetes (T1D), thyroiditis, lupus, rheumatoid arthritis, or pSS, can be present years to decades before the onset of disease manifestations (11) (12) (13) (14) (15) (16) (17) . In pSS, autoantibodies to several self-antigens are common. Anti-Ro/SSA and anti-La/SSB autoantibodies directed against nuclear antigens are a hallmark of disease and are associated with increased disease activity, salivary gland infiltration, and extraglandular manifestations (18) . However, the direct role of these autoantibodies in glandular pathogenesis is unclear (19) . Anti-Ro/SSA and anti-La/SSB autoantibodies appear in the blood years before the onset of symptoms (14, 17) , although they can also be found in saliva once the disease manifests (20) . Autoantibodies to the acetylcholine muscarinic type 3 receptor (M3R), a receptor that regulates exocrine secretion and smooth muscle contraction, are also common in pSS and are thought to be directly involved in secretory dysfunction of pSS (21) (22) (23) . Detection of autoantibodies years before clinical or histologic disease suggests that autoimmunity does not simply arise in local inflamed tissues but rather develops in peripheral immune compartments such as the spleen, where autoreactive cells then traffic to target tissues and drive disease manifestations later in life. It is therapeutically important to understand the mechanisms initiating these early autoimmune events and the resultant pathogenic features that occur.
Nonobese diabetic (NOD) mice are an autoimmune strain of mice that develop spontaneous T1D as well as autoantibodies such as antiinsulin autoantibodies (24) . When made congenic for the B10.A(4R) (H-2 h4 ) strain-derived major histocompatibility complex (MHC) haplotype (NOD.H-2h4), these mice are no longer T1D-susceptible but develop a disease closely resembling pSS, including linkage to females, characteristic anti-Ro/La autoantibodies, and inflammation of the salivary gland resulting in xerostomia/dry mouth (25, 26) . We have previously characterized the TLSs that develop in the salivary glands of these NOD.H-2h4 mice and found that the TLSs organize into defined B cell and T cell regions containing FDC networks and dendritic cells (DCs), respectively, with PNAd + high endothelial venules and occasional germinal centers (27) . Furthermore, similar to human disease, autoantibodies arise before the emergence of salivary gland TLSs in these mice, coinciding with the appearance of spontaneous germinal centers of the spleen (27) . Aberrant regulation of germinal centers has also been implicated in several other autoimmune strains, including NOD mice, as well as in human autoimmune syndromes (6, 28) , suggesting a pivotal role in disease development. NOD.H-2h4 mice also develop spontaneous autoimmune thyroiditis (SAT) when exposed to sodium iodide (NaI), resulting in thyroid inflammation, destruction of thyroid follicles, and anti-mouse thyroglobulin (MTg) autoantibodies (29) .
Here, we studied diseases that arise in both NOD and NOD.H-2h4 mice to understand the origin of autoreactivity and subsequent transition into fully manifested disease. We hypothesized that autoimmune specificities first arise in early-life lymphoid compartments and are then amplified in TLSs of local tissues, resulting in overt disease pathology. Collectively, using three different autoimmune disease models, our findings highlight the contribution of CD40 to early-life immune dysregulation culminating in organ-specific autoimmunity.
RESULTS

Early immune activation drives autoimmunity that develops in aged mice
Previously, we have characterized the kinetics of TLS neogenesis of female NOD.H-2h4 mice and have shown that full establishment of TLSs in the salivary gland does not occur until 24 weeks of age, where organized B cell and T cell regions that contain FDC, DC, and occasional germinal centers are noted (27) . Because CD40 is a key mediator of both immunity and autoimmunity, the requirement of CD40 signaling for the development of salivary gland TLSs (as defined by foci of 50 or more hematopoietic cells clustered together often around individual excretory ducts) was evaluated in aged female NOD.H-2h4 mice. Notably, 6-monthold mice devoid of CD40 expression (CD40 −/− ) showed a complete absence of salivary gland TLSs compared to age-matched CD40-sufficient (Control) mice, where salivary glands were heavily infiltrated with organized B cell and T cell regions [ Fig. 1 , A, B (left panel), and C]. To determine whether early-life CD40/CD40L (CD40 ligand) interactions contributed to the development of TLSs, we administered a single injection of anti-CD40L to female NOD.H-2h4 mice at 4 to 5 weeks of age, months before detectable salivary gland TLSs appeared. Surprisingly, a single dose of anti-CD40L early in life abolished salivary gland TLSs in aged mice [ Fig. 1 , B (right) and C]. Consistent with immunohistology, flow cytometry confirmed that early-life anti-CD40L resulted in a marked and significant reduction of B cells and T cells infiltrating the salivary gland ( fig. S1 ). To understand whether early CD40L blockade was abolishing TLSs by inhibiting CD40/CD40L interactions on hematopoietic cells, presumably B cells and T cells, or rather by interfering with CD40 signaling potentially expressed on salivary gland epithelial or endothelial cells, we established radiation chimeras. Consistent with Fig. 1A , the transfer of wild-type (WT) NOD.H-2h4 bone marrow into lethally irradiated WT NOD.H-2h4 recipients, or CD40 −/− NOD.H-2h4 bone marrow into CD40 −/− recipients, recapitulated the requirement of CD40 for the development of salivary gland TLSs in aged mice (Fig. 1D) . Notably, CD40 expression on hematopoietic but not stromal cells was required for the development of TLSs, as TLSs were visible when WT bone marrow was transferred into CD40 −/− recipients but completely absent when CD40 −/− bone marrow was transferred into WT recipients (Fig. 1D) . Together, these data show that CD40 on hematopoietic cells is a major driver of salivary gland TLSs in NOD.H-2h4 mice.
To understand the molecular pathways associated with diminished TLS neogenesis induced by CD40 blockade, we determined gene expression from whole salivary gland RNA of 8-to 24-week-old mice that received a single injection of anti-CD40L at 4 weeks of age. At week 8 (4 weeks after treatment), no genes showed statistically significant expression difference [fold change ≥2 and false discovery rate (FDR) ≤0.05] between control (Ctrl) and anti-CD40L-treated mice. At 16 and 24 weeks, 48 and 55 genes showed statistically significant down-regulation in anti-CD40L-treated mice compared to control (fold change ≥2; FDR ≤0.05) (Fig. 2 and table S1 ). Notably, about half of all down-regulated genes were related to B cell phenotype or function. B cell-related genes included Cd19, Cd20, Cd79a/b, Bcma, Taci, as well as Pou2af1, required for germinal center formation (30) , and Lpxn, a negative regulator of B cell signaling and function ( Fig. 2A) (31) . In control mice, expression of the B cell-related genes increased with time and disease progression, where, strikingly, eight immunoglobulin genes and Mzb1, which promotes immunoglobulin M (IgM) assembly and secretion (32) , were among the earliest responsive genes. Despite only one early anti-CD40L treatment, these B cell-related genes remained low throughout the study, indicating the suppression of B cell numbers and function (Fig. 2B) . Genes that exert function on multiple lymphocyte types-such as Cd3d (expressed on all T cells), Maf [a gene, among other functions, that is involved in T follicular helper (Tfh) cell differentiation] (33), Cd52 (the Campath-1 antigen expressed on all lymphocytes), and Cd53 (expressed on leukocytes, including B cells, T cells, and natural killer cells, and involved in cell signaling)-were also down-regulated. Genes repressed by anti-CD40L, such as Cd53 and Ighm, are significantly up-regulated in the pSS salivary gland in human disease and have been reported to be potential biomarkers of disease (34) .
Additional genes were found to be significantly repressed by anti-CD40L, but their expression showed distinct temporal patterns. The first group of genes, such as Prg2, Slpi, and Glipr1, showed increased expression in control mice at 16 and 24 weeks, with sustained inhibition at both time points in anti-CD40L-treated mice ( Fig. 2C and table S1 ). The second group of genes also showed increased expression in control mice at 16 and 24 weeks but were inhibited transiently only at 16, but not 24 weeks, in anti-CD40L-treated mice, and included genes involved in circadian rhythm, such as Per3 and Dbp, suggesting a previously unappreciated role of CD40L in pSS pathology. A third group of genes did not abundantly appear in control mice until week 24 and, despite their late expression in the salivary glands, systemic anti-CD40L administration at 4 weeks of age inhibited gene expression 20 weeks after treatment (Fig. 2C) . Included in these late-appearing genes are Plac8, Fam26f9, Serpina3g, Clec7a, Arhgap15, and MHC H2-M3. Together, these results suggest that transient blockade of CD40L in young animals has downstream impacts on several pathways and not simply a reflection of loss of B cell phenotype and function.
To assess the biological processes and signaling pathways that are affected after early-life CD40L neutralization, we performed gene set enrichment analysis (GSEA). Systemic anti-CD40L treatment at 4 weeks of age resulted in a down-regulation of the CD40 signaling pathway in the salivary gland of 16-and 24-week-old mice (Fig. 3 and fig. S2A ). CD40L blockade in young mice also resulted in down-regulation of other immunologic pathways in the salivary gland, including chemokine, lymphocyte activation, lymphocyte/nonlymphocyte interaction, and interleukin-12 (IL-12) signaling, at 16 and 24 weeks of age ( Fig. 3  and fig. S2A ). Anti-CD40L also significantly down-regulated interferon (IFN)-responsive genes and T helper 1 (T H 1)/cytotoxic-related genes as early as week 8 and persisted at week 24, where additional genes were found to contribute to the enrichment (Fig. 3 and fig. S2B ). Thus, the effect of anti-CD40L extends far beyond B cells themselves and speaks to the interconnection of these cell types and pathways to their involvement in pSS immunopathology.
Autoimmune germinal centers of the spleen predate and are required for salivary gland infiltration of aged mice Previously, we reported that spontaneous splenic germinal centers emerge in female NOD.H-2h4 mice at 8 weeks of age, before the detection of autoantibodies and TLSs in the salivary gland (27) . We have now further found that splenic germinal centers were detected in these mice as early as 3.5 weeks of age (Fig. 4A) . Notably, these germinal centers did not resolve, as do germinal centers that form after immunization, but rather persisted for the life of the animal (Control; Fig. 4 , B and C), suggesting that aberrant regulation of molecules was involved in these processes. Germinal center formation to T-dependent antigens requires CD40/CD40L interactions (5). To determine whether there was a connection between the emergence of spontaneous germinal centers in the spleens of young autoimmune female NOD.H-2h4 mice and the ability of early anti-CD40L to abolish salivary gland TLSs later in life, we examined the effect of anti-CD40L on splenic germinal center formation. Notably, treatment with a single injection of anti-CD40L between 4 and 6 weeks of age was found to effectively disrupt spontaneous germinal centers of the spleen for an extended period, in which a 10-fold reduction of germinal center B cell frequency was observed at 1 to 2 weeks after treatment (Fig. 4, B to D) . Germinal centers remained significantly reduced until reemergence starting at week 16 and did not revert to predose frequencies until week 24 (Fig. 4C ). These data show that early anti-CD40L inhibits both splenic germinal center formation and TLS neogenesis.
To identify whether anti-CD40L was acting systemically on both splenic germinal centers and nascent exocrine gland TLSs or whether effects in the splenic germinal centers were sufficient to abrogate exocrine TLS development, young female mice were splenectomized, and the resulting effect on salivary gland TLSs of aged mice was determined. Control mice that received an early-life sham splenectomy developed large TLSs in their salivary gland by 6 months of age with clear B cell (B220)/T cell (CD3) regions (Fig. 4E) . Strikingly, splenectomy of young animals (3.5 to 4 weeks of age) resulted in a marked reduction in the size and number of TLSs in 6-month-old mice (Fig. 4, E and F) . Collectively, these findings suggest that TLS in aged mice is a result of early-life immune dysregulation where the splenic microenvironment plays a major role in that early intervention, and anti-CD40L treatment or splenectomy effectively eliminates salivary gland infiltration.
Inhibition of defined autoantibody specificities accompanies loss of TLS Although the Ro52/SSA autoantigen is up-regulated in inflamed salivary glands of pSS patients (35), anti-Ro/SSA and La/SSB autoantibodies 
H-2h4 mice was transferred into lethally irradiated 8-week-old recipients as described in Materials and
Methods, and the number of TLSs in the salivary gland was determined at 24 to 26 weeks of age. Data (means ± SEM) represent one of two independent experiments. ****P < 0.0001. n.s., not significant.
arise years before the onset of clinical manifestations (14, 17) , suggesting that the original response to the autoantigens does not occur in local inflamed tissues, but rather early in peripheral compartments. Our data showing that early germinal centers are present in the spleen before disease onset suggest that these animals are a good model to study the evolution of exocrine autoimmunity. Therefore, we next characterized the preclinical kinetic development of autoantibody specificities by assessing responses against 95 autoantigens longitudinally in NOD.H-2h4 mice. Of the 95 specificities tested, 40 were found to have a positive signal [signal-to-noise ratio (SNR), >3; intensity, >50] (table S2) . Of these, a wide range of autoantibodies were elevated before the onset of salivary gland inflammation, including pSS-associated autoantibodies to Ro52/SSA and La/SSB as well as myeloperoxidase (MPO), which is abundantly expressed by neutrophil granulocytes and common in vasculitis, Jo-1, found in polymyositis, and many other autoantibody specificities ( fig. S3A ). These antibodies appeared as early as 6 to 8 weeks of age and emerged throughout the life of the animal (table S2) . Reactivity to fibrinogen IV, single-stranded DNA (ssDNA), PL-12, histone H-1, and U1-snRNP BB emerged much later in life, coinciding with the full development of TLSs at 24 weeks of age (fig. S3B and table S2 ). These data suggest that although some autoantibody specificities are triggered in the inflamed salivary glands during the disease process, reactivity to many self-antigens predates disease pathology and arises in peripheral lymphoid compartments. The effect of early-life anti-CD40L on the kinetics of autoantibody emergence was next evaluated. A single administration of anti-CD40L at 4 weeks of age was very effective at reducing autoantibody levels to many but not all self-antigens (31 of the 40 autoantibodies that were positive in the autoantigen array). All autoantibodies that arose in untreated animals by 6 to 8 weeks of age were inhibited by anti-CD40L, such as antibodies to Ro52. Moreover, autoantibodies directed to other nuclear proteins, such as Ro60, La, and Jo-1, were also significantly inhibited or delayed ( Fig. 5A and table S2 ). Anti-CD40L also inhibited several autoantibody specificities that did not appear until weeks 16 and 24, such as antibodies to complement (C1q), fibrinogen IV, and MPO (Fig. 5A) . However, there were several autoantibody specificities that were not affected by early blockade of the CD40L pathway, such as antibodies to Sm, U1-snRNP, and ssDNA self-antigens ( Fig. 5B and table S2 ). Autoantibodies to M3R, which have been shown to play a role in exocrine dysfunction in NOD mice (22, 23) , were detected in the serum of female NOD.H-2h4 mice and increased with age, coinciding with full development of glandular inflammation ( fig. S3C ). Despite the late appearance of this autoantibody specificity at 25 weeks of age, early administration of anti-CD40L significantly inhibited the development of anti-M3R autoantibodies compared to control mice (Fig. 5C ). Together, these data demonstrate that the ability of early anti-CD40L to inhibit autoantibodies was not solely a function of when they appeared, but rather dependent on autoantigen specificity.
Early prophylactic anti-CD40L inhibits development of autoimmune thyroiditis and T1D NOD.H-2h4 mice also develop autoimmune thyroiditis after receiving NaI in the drinking water (29, 36) . To understand whether early prophylactic blockade of CD40/CD40L interactions also has the ability to inhibit SAT, a single injection of anti-CD40L was given to young female NOD.H-2h4 mice, 1 to 2 weeks before NaI. As shown in Fig. 6A , large inflamed thyroids, containing clusters of CD3 + T cells and B220 + B cells that formed TLSs, were noted in 14-to 16-week-old control mice that received NaI 8 weeks before examination (Fig. 6A, left, and fig. S4 ). In stark contrast, mice that received early anti-CD40L monoclonal antibody (mAb) followed by NaI were found to have smaller thyroids with significantly reduced SAT severity scores that reflected markedly reduced lymphocytic infiltrate of T cells and B cells when evaluated at 14 to 16 weeks of age [ Fig. 6, A (right) and B, and fig. S4 ]. Anti-MTg autoantibodies that are associated with increased thyroiditis severity scores and disease pathology (37) were also inhibited by early treatment of anti-CD40L mAb (Fig. 6C) . CCR7  CD83  SNN  PLEK  NFKBIE  RGS1  IRF4  RAC2  CR2  TRAF1  SLAMF1  CD40  BATF  TNFAIP8  GADD45B  PLXNC1  LTA  STAT1  ICOSLG  CCL3  IL1B  NCKAP1L  TAP1  CCL4  NCF2  LGALS1  DUSP2  CD74  MYB  JUNB  ADAM8  TNF  MEF2C  MAP3K8 Type I IFN genes   CCL8  IFIT3  PSMB9  IFI44  CXCL10  PSMB8  GBP2  IRF7  BST2  GBP1  CASP1  ISG20  IFI27  STAT1  TNFSF10  OAS2  CXCL11  NMI  TAP1  EIF2AK2  TRIM21  IFI35 CXCL9  KLRD1  GIMAP7  GIMAP4  GIMAP8  CD5  CD28  CCL8  GZMK  SH2D1A  IRF4  CXCL10  USP18  NKG7  SLAMF1  IL4I1  PTGER2  PRKCQ  RTP4  STAT4  FBXO39  IFNG  SLA2  CCR5  PLEKHO1  IL21  GZMB  TXK  CXCL11  GPR171  PRF1  IRG1  IL15  IFNB1 KLHDC1 Fig. 3 . Early anti-CD40L treatment repressed multiple biological pathways involved in inflammation and autoimmunity. GSEA showing pathways down-regulated by a single treatment of anti-CD40L at 4 weeks of age compared to control. Data derived from whole salivary gland RNA of 24-week-old mice. Heat maps show the expression of the core genes that contribute to pathway enrichment (red, high expression; blue, low expression). NES, normalized enrichment score.
We next asked whether this critical early-life immune checkpoint dependent on CD40L/CD40 interactions would also apply to autoimmune T1D that develops spontaneously in NOD mice. Several groups have chronicled the pancreatic infiltrate that develops over time in NOD mice (38) (39) (40) . Although work from the Unanue and Mathis/Benoist laboratories has shown that B and T lymphocytes as well as myeloid cells infiltrate the pancreas (38, 40) , others have reported that organized pancreatic TLSs develop including germinal centers that contain insulinbinding autoreactive B cells (39) . Thus, young female NOD mice were given a single injection of anti-CD40L at 4 weeks of age, and the incidence of diabetes was monitored starting at week 10. In controls, mice begin to become diabetic at 12 weeks of age, consistent with previous reports (41) . Strikingly, at 20 weeks of age, when the cumulative incidence of diabetes in the control group was about 80% in experiment no. 1 and 58% in experiment no. 2, not a single anti-CD40L-treated mouse showed signs of glycosuria. At 30 weeks of age, when experiment no. 1 was terminated, 82% (9 of 11) of anti-CD40L-treated mice remained nondiabetic, whereas only 14% (2 of 14) of control mice remained free of glycosuria (Fig. 6D) . For experiment no. 2, 83% (10 of 12) of control IgG-injected animals presented with glycosuria at 23 weeks of age, where only 8% (1 of 12) of anti-CD40L-treated mice were diabetic at this time (Fig. 6D) . In independent experiments, anti-CD40L mAb was given as a single injection at 4 weeks of age, and the ability of anti-CD40L to inhibit insulitis in the pancreas was determined 8 to 10 weeks later in nondiabetic mice, when mice were either 12 or 14 weeks of age. Consistent with its ability to inhibit tissue infiltration of salivary gland and thyroid tissue of NOD.H-2h4 mice, early and transient anti-CD40L mAb in NOD mice significantly reduced pancreatic insulitis scores in 12-to 14-week-old animals compared to controls (Fig. 6E ). Consistent with NOD.H-2h4 mice, the ability of anti-CD40L to inhibit T1D in NOD mice also corresponded with a statistically significant decrease in spontaneous germinal center B cells in the spleen of these mice (Fig.  6F ). These data show that the ability of prophylactic administration of anti-CD40L to inhibit disease manifestations is not limited to pSS but also proves efficacious for other autoimmune diseases such as thyroiditis and T1D. In summary, we show that early-life immune dysregulation, which manifests as spontaneous germinal centers of the spleen, played a significant role in the initiation of disease manifestations including autoantibodies, TLSs in peripheral tissues, and ultimately sialadenitis, thyroiditis, and diabetes in which CD40 was a key driver of immunopathology ( fig. S5 ).
DISCUSSION
TLSs arise in nonlymphoid tissues in response to chronic immune activation as a result of microbial, environmental, inflammatory, or autoreactive challenges to the host and can cause extensive pathology (42) . Patients with autoimmune conditions that develop TLSs are the most difficult to treat using standard biological therapies (43) . Here, we show that a single injection of anti-CD40L mAb early in life abolished autoimmune manifestations associated with pSS, thyroiditis, and T1D.
Here, early intervention with anti-CD40L inhibited disease development. Work from others has shown that CD40-Fc was not able to inhibit focus score when delivered directly into the salivary glands of aged NOD mice (44) . These data are consistent with our studies that systemic CD40L blockade is not merely inhibiting autoreactivity in local tissues but rather in the splenic microenvironment early in life.
CD40/CD40L interactions are required for the initiation and maintenance of germinal centers (5) and affinity maturation to T celldependent antigens (45) , where signaling through both CD40 and CD40L plays important roles (46, 47) . Aberrant regulation of germinal centers has been implicated in several autoimmune diseases (6, 27, 28) , where CD40 is presumably involved. Previous studies showed that Tfh cells play a critical role in spontaneous germinal center generation and the formation of pathogenic autoantibodies (7, 48, 49) . Our gene expression profile detected a statistically significant decrease in Pou2af1 and Maf expression in salivary gland upon anti-CD40L treatment. MAF, among its other functions, plays a key role in Tfh development (33), whereas IRF4-induced POU2AF1 regulates germinal center B cells (30) . These data suggest that early CD40L blockade may be affecting the presence of Tfh and germinal centers that arise in local tissues, which may be contributing to disease pathology in control mice. IgG autoantibodies unaffected by anti-CD40L treatment compared to control. Data represent n = 11 for control mAb-treated mice and n = 13 for anti-CD40L-treated mice from three independent experiments. AU, mean normalized fluorescence IgG signal ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (C) End point titer (means ± SEM) of anti-M3R IgG autoantibodies in sera from of 20-to 26-week-old female NOD.H-2h4 mice that received a single treatment of either isotype control antibody (n = 12) or anti-CD40L antibody (n = 15) at 4 weeks of age. Data represent two independent cohorts.
In the NOD.H-2h4 animal model and in human disease, there is a female predisposition to pSS. It is possible that the appearance of spontaneous germinal centers in the spleens of female NOD.H-2h4 mice was prompted by estrogen, as their emergence coincided with the first estrus cycle that begins at 25 to 30 days of life. Estrogen has been reported to predispose to autoimmunity by influencing B cell tolerance induction and allowing for the activation of autoreactive B cells that produce highaffinity antibodies to self-antigens (50) . Here, the preponderance of spontaneous germinal centers that developed in the spleens of young NOD.H-2h4 mice was followed by the emergence of numerous autoantibodies. Many of these autoantibodies react with nuclear antigens, cell surface antigens, components of the extracellular matrix, and receptors required for physiological secretion of saliva (M3R). Some autoantibodies were detected as early as 6 to 8 weeks of age (anti-Ro52), whereas others arose much later at 24 weeks of age (anti-ssDNA). It is likely that antibodies that arose before the initiation of salivary gland inflammation exacerbated the development of TLSs through immune complex deposition with self-antigens. Release and exposure of other selfantigens in the salivary gland during the initial inflammatory response would in turn result in activation of autoreactive cells and emergence of tissue-specific autoantibodies to antigens such as M3R. The late appearance of anti-M3R autoantibodies and others, such as anti-fibrinogen IV, anti-ssDNA, anti-Sm, and anti-U1-snRNP, suggests that autoreactivity to these self-antigens arose locally in the inflamed salivary gland once TLSs were fully formed. This is supported by studies showing that antiRo/SSA and anti-La/SSB autoantibody-producing cells are present in salivary glands from patients with Sjögren's syndrome (3, 51) as well as plasma cells present in labial salivary gland that produced inhibitory anti-M3R autoantibodies (52), suggesting a direct pathogenic role of these locally produced autoantibodies.
The spleen is important for both immunity and autoimmunity. Splenectomy of immune thrombocytopenic purpura (ITP) patients, where long-lived plasma cells to platelet antigens are found (53) , results in a complete remission rate of more than 75% (54) . Moreover, splenectomy of ITP patients with systemic lupus erythematosus results in a partial or complete response rate of 88% (55) . Here, we report that splenectomy of young mice also prevented disease manifestations, demonstrating the importance of this lymphoid compartment in early life to the contribution of autoimmunity that develops in aged mice. Although inflamed tissue is believed to be the site where autoreactivity to local self-antigens is triggered, our data suggest that early immune dysregulation to selfantigens in the spleen is the initial trigger, and this response is then amplified in TLSs that develop in local tissues later in life, ultimately resulting in disease progression.
Early-life interventions on TLSs in NOD.H-2h4 mice underscore the significance of neonatal immune checkpoints. Others have shown that an early-life window exists where clinical disease can be inhibited by prophylactic therapy. For example, neutralization of TNF in young Fig. 6 . Early anti-CD40L mAb inhibits autoimmune thyroiditis and diabetes. (A to C) Female NOD.H-2h4 mice were treated with a single dose of isotype control or anti-CD40L mAb at 5 to 6 weeks of age, and 7 to 10 days later, they were given 0.08% NaI in their drinking water for 8 weeks. (A and B) Thyroids were removed from 14-to 16-week-old mice, and severity scores (means ± SEM) were determined from hematoxylin and eosin-stained slides. (A) SAT severity scores are 2+ for control and 0 for anti-CD40L mAb. Scale bars, 100 mM. (B) SAT severity scores were determined as previously described in detail (29, 37) . (C) Autoantibody to MTg was measured in mice as described in (A) at 14 to 15 weeks of age. Data (means ± SEM) are from three independent experiments of n = 12 for control mAb and n = 18 for anti-CD40L-treated mice. (B and C) ****P < 0.0001. Ab, antibody. (D) Female NOD/LtDvs mice were treated with a single dose of anti-CD40L mAb at 4 weeks of age and followed for diabetes incidence starting at week 10. These mice were compared to either non-antibody-injected control mice (experiment no. 1; ***P = 0.0002) or isotype control-injected antibody (experiment no. 2; ***P = 0.0001). (E) Female NOD/LtDvs mice were treated with a single dose of anti-CD40L mAb at 4 weeks of age, and insulitis was compared to age-matched untreated control mice as described in Materials and Methods at 12 or 14 weeks of age in nondiabetic mice. Data (means ± SEM) represent two independent experiments. ***P = 0.0005. but not aged NOD mice inhibits insulitis and delays T1D development (56) . Furthermore, prophylactic blockade of IFN-a also significantly inhibits T1D (57) . Consistent with our data, previous studies reported that blocking CD40L starting early in life inhibited T1D development in NOD mice (58) . However, in these studies, anti-CD40L was administered for several months with an anti-CD40L hamster antibody capable of depleting CD40L-expressing cells. In contrast, our studies used an MR1 anti-CD40L antibody that was engineered as a human IgG1 TM (triple mutant) devoid of effector function (7), where a single injection of anti-CD40L at 4 weeks of age was sufficient to significantly block T1D development in NOD mice until the experiment was terminated at 30 weeks of age. These data support our findings and suggest that in diseases where autoantibodies predate clinical signs, there is a treatment window where therapeutic intervention may be able to prevent disease development.
Here, anti-CD40L disrupted early autoreactive immune responses. CD40/CD40L has been implicated in a variety of autoimmune diseases in which B cell and T cell activation plays an essential role in pathogenesis (4). In pSS, both CD40 and CD40L are expressed on epithelial cells and infiltrating immune cells of the salivary gland that has the potential to contribute to disease pathology (8, 10) . Disrupting this pathway could affect the development of autoimmunity through several mechanisms. In radiation chimera experiments, we show that CD40 expression on hematopoietic but not stromal cells is required for the development of TLSs. Moreover, early and transient blockade of CD40/ CD40L interactions between DCs (or any antigen-presenting cell) and T helper subsets may contribute to dampening pathology by reducing autoreactive T cell activation and expansion, which would in turn limit autoantibody development. In support of this, CD40L blockade has been shown to have an impact on DC priming of autoreactive T cells (59) . In our GSEA studies, a statistically significant decrease in IL-12 signaling was detected in the salivary gland of anti-CD40L-treated mice. IL-12 production is induced during the interaction of DCs with T cells, mainly through CD40/CD40L interaction (60) .
Treatment with anti-CD40L antibody modulated the expression of genes in exocrine tissue not typically associated with immune responses. Our gene expression profile of salivary gland revealed that CD40L blockade had a broader impact on multiple biological processes, suggesting novel mechanisms of pSS pathogenesis. Some of these are likely related to the normalization of the tissue in the absence of fulminant autoimmunity, whereas others may reflect novel CD40/CD40L-regulated pathways. Genes involved in innate immunity and tissue inflammation, such as Clec7a (Dectin-1) (61), Arhgap15 (62), and Fam26f9 (63), were inhibited by anti-CD40L. Several genes modulated by anti-CD40L have been described to be involved with bone formation including Ogn (osteoinductive factor) (64), Igfbp5 (65), and Lpxn (66), where notably twothirds of pSS patients have been described with evidence of subclinical impaired bone health (67) .
NOD.H-2h4 mice also develop thyroid disease when given NaI in the drinking water (29, 36) . Tef, which binds to and transactivates thyroidstimulating hormone, beta (68) , was found to be down-modulated by early anti-CD40L, suggesting a novel role by which CD40L blockade inhibits SAT in this animal model. Tef has also been implicated in circadian regulation of insulin production (69) . Circadian clock genes are expressed in the salivary gland where salivary flow follows circadian rhythms. Alterations in this pathway have been suggested to contribute to reduced saliva production in pSS patients (70) . Additional circadian rhythm-related genes that were repressed by CD40L blockade include Per3 and Dbp. These findings linking CD40 to circadian clock regulation suggest new molecular pathways involved in disease pathogenesis and warrant further investigation.
NOD.H-2h4 mice do not become diabetic because of loss of the pathogenic H2 g7 MHC haplotype. However, NOD mice contain more than 30 other diabetic susceptibility genes that contribute to the development of autoimmunity (24) . In the salivary gland, several genes that were suppressed by anti-CD40L are genes that have been reported to be associated with T1D and/or insulin regulation, including Serpina3g (71), Iapp (72), Maf (73), and Igfbp5, where Igfbp5 is contained within IDDM13 susceptibility locus (74) .
Although early clinical trials with anti-CD40L showed promising immunomodulatory effects, thromboembolic complications halted trials (75) . New strategies are being developed to avoid platelet aggregation, such as monovalent anti-CD40L antibodies (76), CD40L antagonist scaffolds engineered to avoid FcR binding (ClinicalTrials.gov identifier: NCT02151110), or antibodies to CD40 such as ASKP1240 (77) (ClinicalTrials.gov identifiers: NCT01780844 and NCT01585233), or the Fc-silent anti-CD40 antibody CFZ533 (78) that is currently in clinical trial for pSS (ClinicalTrials.gov identifier: NCT02291029), rheumatoid arthritis (ClinicalTrials.gov identifier: NCT02089087), and several other indications. The ability of prophylactic anti-CD40L to dissolve germinal centers and halt autoimmune humoral responses in our studies suggests that biologics that target CD40/CD40L interaction may have efficacy in diseases that are predated by the appearance of autoantibodies.
The findings we report have some limitations in regard to the clinic. To translate into the clinic, further investigation including examination of longitudinal samples obtained from human subjects before and after the emergence of overt disease manifestations would need to be evaluated to determine specific pharmacodynamic markers. Findings and correlations from such studies could then be mechanistically investigated using mouse models of disease such as the ones we report in this manuscript. Biomarkers that unequivocally indicate early-life immune dysfunction are needed to distinguish those patient populations that will progress to full disease states versus otherwise healthy individuals.
MATERIALS AND METHODS
Study design
The objective of this study was to evaluate the contribution of early-life CD40-CD40L signaling to downstream autoimmune manifestations. These studies involved either antibody-mediated blockade or genetic deletion of CD40-CD40L signaling in several mouse models of autoimmunity, including NOD.H-2h4 and NOD mice. To assess the effect of anti-CD40L on TLS development in NOD.H-2h4 mice, we performed a pilot experiment in which mice were treated at 4, 5, or 6 weeks of age. Data obtained from these mice at 6 months of age, a time when TLSs fully develop, was then used to estimate the number of animals and experiments needed to achieve statistical significance with 80% power. Female mice within the same age group were randomized into treatment and control groups, and quantification of TLS number was performed in a blinded manner. To evaluate the effect of anti-CD40L on autoimmune thyroiditis, mice were randomized to either control or treatment groups, and quantitation of histology was blinded. For T1D studies, the number of mice in the experiments was sufficient to detect the difference between control and anti-CD40L-treated groups with 90% power. NOD mice treated with either control IgG or anti-CD40L were from two or more litters of different parents that were randomized before treatment. The investigator doing the histology scoring was blinded to the groups of mice in any given sample at the time of evaluation. For all studies, the number of independent experiments and the number of mice per experiment are indicated in the figure legends.
Mice NOD.H-2h4 (stock no. 004447) (26) and C57BL/6J mice were obtained from The Jackson Laboratory, and the colonies were maintained at the MedImmune mouse facility or the animal facility at the University of Missouri. CD40
−/− female NOD.H-2h4 mice (Mutant Mouse Resource and Research Center no. 037352), as described previously (29), were maintained at the at the MedImmune mouse facility. NOD/LtDvs (NOD) mice were maintained at The Jackson Laboratory. Mice were housed under pathogen-free conditions. All experiments were performed with female mice. All animal protocols were carried out in accordance with and approved by MedImmune (protocol nos. MI-12-012 and MI-15-0006), University of Missouri (protocol no. 8195), or The Jackson Laboratory (protocol no. 99063) Institutional Animal Use and Care Committees.
Anti-CD40L mAb and treatment
The mouse CD40L TM mAb used is an in-house modified version of the commercially available MR1 clone that was engineered to contain the Fc region of the human IgG1 with TM in the CH2 region to prevent Fc-mediated effector function (79) . For the Sjögren's studies, NOD.H2h4 female mice were treated intravenously at various ages with a single injection of anti-CD40L (TM) or human IgG1 isotype control TM mAb at 20 mg/kg as described previously (7). Mice were serially bled for serum analysis until the end of the study. Four weeks to 6 months after treatment, mice were sacrificed, and spleens and salivary glands were assessed for the effect of anti-CD40L treatment. For the thyroid studies, NOD.H2h4 female mice were treated intravenously at 5 to 6 weeks of age with a single injection of 400 mg of either anti-CD40L (TM) or human IgG1 TM isotype control mAb. Seven to 10 days later, they were given 0.08% NaI in their drinking water, and thyroids were removed 7 to 8 weeks later. For diabetes studies, NOD/LtDvs mice were injected intraperitoneally with 400 mg of either anti-CD40L (TM) mAb or human IgG1 TM isotype control mAb at 4 weeks of age and monitored for glycosuria and insulitis as described below.
Measurement of salivary gland TLS
Whole salivary glands were removed from female NOD.H-2h4 mice at the indicated ages. Tissues were formalin-fixed and embedded in paraffin for hematoxylin and eosin staining. In all the studies, the counts were done in a randomized, blinded fashion. For enumeration, in most of the experiments, serial sections of both lobes of the salivary glands were cut at least at three different planes, each plane being 50 mm apart. Graphed data represent the highest count of TLSs, as defined by foci of 50 or more hematopoietic cells clustered together often around individual excretory ducts, in any one of the three section planes examined. In some experiments, TLSs were also enumerated from immunohistology sections stained for B cells and T cells as described below. For these experiments, one TLS was counted when foci of 50 or more T cells and/or B cells were clustered together. ) were transferred intravenously into lethally irradiated 8-week-old female WT or CD40 −/− NOD.H-2h4 recipients. Salivary glands were removed at 24 to 26 weeks of age, and the number of TLSs in both lobes of the salivary gland was determined in hematoxylin and eosin-stained sections. For enumeration, serial sections through both lobes of the salivary gland were cut at least at three different planes, each plane being 50 mm apart. The highest count of TLSs in any one of the three section planes examined represents data shown.
Measurement of autoimmune thyroiditis
After treatment as described above, thyroids were removed and fixed in formalin, sectioned, and either stained with hematoxylin and eosin or stained for expression of CD3 and B220 by IDEXX RADIL. SAT severity scores were determined as previously described in detail (29) . Serum was obtained at the same time, and MTg-specific IgG autoantibodies were measured by enzyme-linked immunosorbent assay (ELISA) as previously described (29) . Results are expressed as OD 410 (optical density at 410 nm) of a 1:50 dilution of duplicate serum samples from individual mice.
Measurement of T1D and insulitis
After mAb treatment at 4 weeks of age, NOD/LtDvs mice were monitored for glycosuria with Ames Diastix (Bayer Diagnostics Division) starting at 10 weeks of age. Mice with two consecutive values of ≥3 were scored as diabetic. In a separate experiment, mice received anti-CD40L mAb at 4 weeks of age, and nondiabetic mice were assessed for insulitis at 12 or 14 weeks of age and compared to untreated agematched nondiabetic control mice. Pancreas tissues were fixed in Bouin's solution, sectioned at 3 levels (70 mm apart), and stained with aldehyde fuchsin to detect beta cells. Islets (at least 20 per mouse) were individually scored in a blinded manner as follows: 0, no lesions; 1, periinsular leukocytic aggregates, usually periductal infiltrates; 2, <25% islet destruction; 3, >25% islet destruction; and 4, >75% or complete islet destruction. An insulitis score for each mouse was obtained by dividing the total score for each pancreas by the number of islets examined.
Splenectomy
Young mice (3.5 to 4 weeks old) were anesthetized with 2 to 3% isoflurane and injected with buprenorphine (0.05 mg/kg). A 1-cm skin incision on the left lateral surface of the abdomen was made before separating the skin from the peritoneal wall. A similar incision was made in the peritoneal wall, and the spleen was pulled out with forceps. The splenic artery at the base of the spleen was tied off before the spleen was removed by cutting distally to the suture. For the sham splenectomy control group, mice were anesthetized, and the body cavity was opened as described above. The skin was closed with staples, and mice were allowed to recover on a heating pad. Mice were monitored for 48 hours for signs of distress and received two doses of buprenorphine on the day of surgery and a single dose the following morning. Salivary glands were then harvested at 6 to 6.5 months of age for evaluation of TLS enumerated as described above.
Immunofluorescence microscopy Salivary gland and splenic tissue were removed from female NOD.H2h4 mice at the indicated ages. Tissues were embedded in O.C.T. (optimal cutting temperature) compound (Tissue-Tek) and frozen on dry ice. Frozen tissue sections (5 to 7 mm) were fixed in acetone for 5 min and stained with the following primary antibodies: antiIgM-Texas Red (SouthernBiotech), anti-B220 (rat), anti-CD3 (hamster),
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and biotinylated peanut agglutinin (Vector Laboratories). All primary antibodies were from BD Biosciences except where indicated. The following secondary antibodies were used: anti-hamster Alexa Fluor 488, anti-rat-Oregon Green, and streptavidin-Oregon Green. All secondary antibodies were purchased from Life Technologies unless otherwise indicated. Anti-B220 (clone RA3-6B2, BioLegend) was labeled with Alexa Fluor 555 using an antibody labeling kit from Molecular Probes according to the manufacturer's instructions. Fluorescence images were visualized using a Nikon Eclipse microscope and NISElements Advanced Research software.
Flow cytometry
Splenocytes were processed and stained according to standard protocols. Salivary glands were cut into small pieces and incubated in digestion buffer [phosphate-buffered saline (PBS); Liberase TL at 0.04 WU/ml, 0.1% deoxyribonuclease] at 37°for 1 hour in a shaker. The reaction was stopped by the addition of RPMI 1640 supplemented with 10% fetal calf serum. Cells were then filtered and washed with PBS before further downstream applications. The following antibodies were used: anti-B220-PECy7, anti-GL7-FITC (fluorescein isothiocyanate), anti-CD19-V450, CD45-FITC, CD8 PercpCy5.5 (eBioscience), and CD4 APC. All antibodies were obtained from BD Biosciences except where indicated. Cells were analyzed on an LSR II flow cytometer (BD Biosciences) using FACSDiva software. Data were analyzed using FlowJo software.
Autoantigen arrays
Serial serum samples were collected from anti-CD40L or isotype controltreated mice and screened for reactivity to a panel of 96 autoantigens (University of Texas Southwestern Microarray Core Facility, Dallas, TX), as previously described (80) . Data values were only considered positive when the SNR was greater than 3. In addition, signal intensities with values less than 50 were excluded. Of all 96 autoantibodies screened, 40 were tested positive, 2 of which were also detected in C57BL/6 mice at levels equivalent to NOD.H-2h4 mice.
Anti-M3R ELISA Samples of serum from NOD.H-2h4 mice were analyzed for reactivity to M3R peptide to determine the levels of anti-M3R IgG antibodies. Appropriate positive (NOD/Lt serum) and negative (C57BL/6 normal serum) assay controls were included on each plate. Antibody quantities were determined as serum end point titers. The assay was performed by KWS BioTest, Cambridge, U.K.
Microarrays
Salivary glands were isolated and immersed in Allprotect Tissue Reagent (Qiagen) at 4°C for 24 hours before storage at −20°C. At the time of processing, the samples were thawed, and excess Allprotect Tissue Reagent was removed before tissue homogenization and RNA extraction according to the manufacturer's protocol (Qiagen). Microarray gene expression studies were performed on Affymetrix GeneChip Mouse Genome 430 2.0 Array, and data were analyzed using the limma package from Bioconductor. FDR was calculated using the Benjamini-Hochberg procedure. Genes with fold change ≥2 and FDR ≤0.05 were defined as significant. GSEA (www.broadinstitute.org/gsea/index.jsp) was performed on gene expression of anti-CD40L antibody-treated versus control samples at each time point. Pathways from Molecular Signatures Database (MSigDB) were used. Titles of the pathways were modified for simplicity: type I IFN genes, BROWNE_INTERFERON_ RESPONSIVE_GENES; lymphocyte activation, LYMPHOCYTE_ ACTIVATION; T H 1/cytotoxic, BOSCO_TH1_CYTOTOXIC MODULE; CD40 signaling, BASSO_CD40_SIGNALING_UP; IL-12 signaling, PID_IL12_2PATHWAY; lymphocyte/nonlymphocyte interaction, REACTOME_IMMUNOREGULATORY_INTERACTIONS_ BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL; and chemokines, REACTOME_CHEMOKINE_RECEPTORS_BIND_ CHEMOKINES. Heat maps of gene expression and other statistical analysis were performed using R programming software. Microarray data have been deposited at the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (www.ncbi.nlm.nih. gov/geo/query/acc.cgi?acc=GSE83862) with accession code GSE83862.
Statistics Two-tailed unpaired Mann-Whitney U test was used for group comparisons between control and anti-CD40L-treated or splenectomized NOD.H-2h4 mice (Figs. 1C, 4F, and 6C) . The "age of detection" for autoantibodies in NOD.H-2h4 mice (table S2) and the significance for fig. S3 were determined when autoantibodies were significantly elevated compared to baseline (4 weeks of age). Statistical significance for both age of detection (table S2) and fig. S3 was determined using a one-tailed paired Student's t test when the data followed normal distribution, or paired Mann-Whitney U test when the data did not follow normal distribution as determined by D'Agostino and Pearson omnibus normality test. The effect of anti-CD40L on germinal center B cell frequency was determined using a two-tailed unpaired Student's t test (Figs. 4D and 6F ). The ability of anti-CD40L to inhibit autoantibody levels compared to control in NOD.H-2h4 mice ( Fig. 5A and table S2 ) was determined using one-tailed unpaired Student's t test if the data passed F test for equal variance, or Mann-Whitney U test if the data did not pass F test. For thyroid experiments in NOD.H-2h4 mice (Fig. 6 , B and C), two-tailed unpaired Student's t test was used for MTg autoantibody, and unpaired Mann-Whitney U test was used for SAT severity scores. Incidence of diabetes in NOD mice (Fig. 6D) was compared using the log-rank (Mantel-Cox) test, and insulitis scores (Fig. 6E) were compared using a two-tailed unpaired Student's t test. Statistical tests and plots were performed using GraphPad Prism software. Raw data are provided in table S3.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/8/361/361ra137/DC1 Fig. S1 . Early-life anti-CD40L inhibits lymphocyte infiltration of salivary gland of aged mice. Fig. S2 . GSEA of gene pathways down-regulated in salivary gland by early anti-CD40L treatment of NOD.H-2h4 mice. Fig. S3 . Autoantibodies (IgG) are detected after emergence of spontaneous splenic germinal centers. Fig. S4 . Greatly reduced B cell and T cell clusters in thyroids after early anti-CD40L treatment in NOD.H-2h4 mice. Fig. S5 . Autoimmune manifestations in aged mice arise from early-life germinal centers. Table S1 . Significantly down-regulated salivary gland genes in response to early CD40L blockade. Table S2 . Early-life treatment of anti-CD40L inhibits specific IgG autoantibody profiles. Table S3 . Source data (Excel).
